Skip to main content

AP ISMPP U: Understanding and publishing real-world evidence in Asia Pacific (July 2021)

Please be patient while attendance data is being processed

Thank you

The objectives of the session are:

  • To provide an overview of what RWE is
  • To discuss how RWE studies differ from clinical trials and if there are specific considerations to be aware of (e.g. limitations)
  • To share practical approaches to publishing RWE (e.g. challenges in writing manuscripts (scope creep, lack of study report), journal/congress selection, addressing review comments, multiple publications from databases/registries)

Contributors

  • Nakul Saxena, Senior Manager, Evidence Generation Takeda (Growth and Emerging Markets)

    Nakul is a healthcare professional with several years of work experience in the Singapore healthcare sector (both public and private). A pharmacist from Mumbai, Nakul holds a Ph.D in Clinical Epidemiology (breast cancer research) from the National University of Singapore and a postgraduate accreditation in Health Economics from the University of Aberdeen. He has co-authored over 25 publications and has a keen interest in designing and executing real world evidence (RWE) studies.

  • Bo Lyu, PhD, Senior Medical Writer, Costello Medical

    Bo has 4+ years of medical writing experience and specializes in English–Mandarin bilingual medical communications projects, including English and Chinese peer-reviewed manuscripts.

    Her professional interests include the promotion of good publication practices in the APAC region through author/client liaison and education. Bo currently serves on the ISMPP APET.

  • Sue Neville, ISMPP CMPP™, Senior Scientific Specialist, Parexel Medical Communications

    Sue has worked for over 20 years in medical communications and market access.
    She first worked in medical communications including publication plans in rheumatoid arthritis, IBS, supportive care in cancer, and type 2 diabetes. When working on an increasing number of health economic and PRO publications, and a NICE submission, she decided to return to university to study health economics and healthcare evaluation.

    After completing her MSc including modules on clinical trial design and analysis, health economics, systematic literature reviews, Sue worked as a principal market access writer on global value dossiers and systematic reviews. She joined Parexel in 2019 where she has worked on primarily in oncology publications including real world evidence studies. In 2020 Sue was seconded to AstraZeneca as Global Publications Leader in oncology and gained further experience of publication planning.

    Sue holds an MA in Natural Sciences from the University of Cambridge and MSc in Health Services Research and Technology Assessment from the University of Sheffield, UK. Sue gained CMPP™ certification in 2019.

  • Ronnie Lin, MSc, MBA, Head of Medical & Scientific Communications, Fosun pharma

    Ronnie has 13 years’ experience in the healthcare industry including positions with medical communications, publishing and pharmaceutical companies. (Parexel, Sanofi, Elsevier). He has experience in primary care, specialty care and rare disease for pre, peri- and post-launch products. He spent 8 years in medical affairs, mainly focused in medical communications (medical information, medical education, scientific publication and digital medical communications). He is an ISMPP board of Trustee, APAC trustee.

    During his carreer, Ronnie has successfully developed publication strategy and tactical publican plan, managed key stakeholder alignment, delivered tailored customization across therapy areas employing multichannel solutions. In addition, he has experience in Scientific exchange material development, and audience segmentation, innovation medical publication solutions.

    Ronnie holds an MBA, Sanofi-Peking University BiMBA program, MBA, Sanofi-Peking University BiMBA program, and BSc, Medicine, Fudan University, Shanghai, China

July 14, 2021
Wed 9:00 PM EDT

Duration 1H 0M

This live web event has ended.

ISMPP U Support